Home > Insider Trading > Filing (0001576885-25-000009)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1576885	Acumen Pharmaceuticals Inc.	ABOS	Biological Products, (No Disgnostic Substances) (2836)	364108129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1866239	Eric Siemers	C/O Acumen Pharmaceuticals, Inc. 1210-1220 Washington Street, Suite 210 Newton MA 02465	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-01-03	10,859	$1.85	106,717	No	4	S	Direct
Common Stock	Acquisiton	2025-01-06	66,800	$0.00	173,517	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2025-01-06	100,300	$0.00	100,300	$1.85

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
100,300		2035-01-06	No	4	A	Direct

Footnotes

Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2024.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7750 to $1.9100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents an RSU award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.
The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.